H1 and H2 Blocker Dosing and Treatment Regimens for Allergic Reactions

Introduction to Treatment Regimens

The American Academy of Allergy, Asthma, and Immunology recommends combining diphenhydramine 25-50 mg (1-2 mg/kg) parenterally with ranitidine 50 mg IV (1 mg/kg in children, diluted in 5% dextrose over 5 minutes) as second-line therapy after epinephrine for acute allergic reactions and anaphylaxis, as this combination is superior to H1 blockade alone 1

For adults, the recommended dose of diphenhydramine is 25-50 mg parenterally, while for children, it is 1-2 mg/kg parenterally 1
The recommended dose of ranitidine for adults is 50 mg IV over 5 minutes, and for children, it is 12.5-50 mg (1 mg/kg) IV, diluted in 5% dextrose to 20 mL total volume, administered over 5 minutes 1
The American Academy of Allergy, Asthma, and Immunology advises against using H1 or H2 antihistamines as monotherapy for anaphylaxis, as they are second-line agents to epinephrine 1

The European Academy of Allergy and Clinical Immunology recommends starting with cetirizine 10 mg once daily, loratadine 10 mg once daily, or desloratadine 5 mg once daily for chronic urticaria, and assessing control after 2-4 weeks using the Urticaria Control Test (UCT score) 2, 3
If inadequate control, the dose of second-generation H1 antihistamine can be increased up to 4-fold the standard dose, as this approach is now common practice when benefits outweigh risks 2, 3, 4
The addition of H2 blockers, such as famotidine 20 mg twice daily, to H1 antihistamines provides better urticaria control than H1 antihistamines alone, particularly for gastrointestinal symptoms 1, 4, 5

The British Society for Allergy and Clinical Immunology recommends adjusting medication timing to ensure highest drug levels when urticaria is anticipated, and choosing cetirizine for its short time to maximum concentration when rapid availability is needed 4
The society also advises against using first-generation H1 antihistamines in elderly patients due to cognitive decline and sedation risk, and recommends halving the dose of cetirizine, levocetirizine, and hydroxyzine in moderate renal impairment 4, 6
In severe renal impairment, cetirizine and levocetirizine should be avoided, while loratadine and desloratadine should be used with caution 4
In severe liver disease, alimemazine and chlorphenamine/hydroxyzine should be avoided due to hepatotoxicity and inappropriate sedation, respectively 4
During pregnancy, all antihistamines should be avoided when possible, especially in the first trimester, although chlorphenamine is often chosen in the UK due to its long safety record 4